Infigratinib FDA Approval Status
FDA Approved: No
Generic name: infigratinib
Company: BridgeBio Pharma, Inc.
Treatment for: Cholangiocarcinoma of Biliary Tract
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of individuals with FGFR-driven conditions, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer) and achondroplasia.
Development Timeline for infigratinib
|Dec 1, 2020||BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.